Psychosocial  ||| S:0 E:13 ||| JJ
vulnerability  ||| S:13 E:27 ||| NN
and  ||| S:27 E:31 ||| CC
early  ||| S:31 E:37 ||| JJ
life  ||| S:37 E:42 ||| NN
adversity  ||| S:42 E:52 ||| NN
as  ||| S:52 E:55 ||| IN
risk  ||| S:55 E:60 ||| NN
factors  ||| S:60 E:68 ||| NNS
for  ||| S:68 E:72 ||| IN
central  ||| S:72 E:80 ||| JJ
sensitivity  ||| S:80 E:92 ||| NN
syndromes  ||| S:92 E:102 ||| VBD
The  ||| S:102 E:106 ||| DT
aim  ||| S:106 E:110 ||| NN
of  ||| S:110 E:113 ||| IN
this  ||| S:113 E:118 ||| DT
narrative  ||| S:118 E:128 ||| JJ
review  ||| S:128 E:135 ||| NN
of  ||| S:135 E:138 ||| IN
the  ||| S:138 E:142 ||| DT
epidemiology  ||| S:142 E:155 ||| NN
of  ||| S:155 E:158 ||| IN
central  ||| S:158 E:166 ||| JJ
sensitivity  ||| S:166 E:178 ||| NN
syndromes  ||| S:178 E:188 ||| NN
is  ||| S:188 E:191 ||| VBZ
to  ||| S:191 E:194 ||| TO
provide  ||| S:194 E:202 ||| VB
a  ||| S:202 E:204 ||| DT
summary  ||| S:204 E:212 ||| NN
of  ||| S:212 E:215 ||| IN
the  ||| S:215 E:219 ||| DT
role  ||| S:219 E:224 ||| NN
of  ||| S:224 E:227 ||| IN
early  ||| S:227 E:233 ||| JJ
life  ||| S:233 E:238 ||| NN
adversity  ||| S:238 E:248 ||| NNS
and  ||| S:248 E:252 ||| CC
psychosocial  ||| S:252 E:265 ||| CD
/  ||| S:265 E:267 ||| CD
psychological  ||| S:267 E:281 ||| JJ
factors ||| S:281 E:288 ||| NNS
,  ||| S:288 E:290 ||| ,
in  ||| S:290 E:293 ||| IN
the  ||| S:293 E:297 ||| DT
epidemiology  ||| S:297 E:310 ||| NN
of  ||| S:310 E:313 ||| IN
six  ||| S:313 E:317 ||| CD
main  ||| S:317 E:322 ||| JJ
syndromes ||| S:322 E:331 ||| NN
:  ||| S:331 E:333 ||| :
( ||| S:333 E:334 ||| -LRB-
i ||| S:334 E:335 ||| FW
)  ||| S:335 E:337 ||| -RRB-
fibromyalgia  ||| S:337 E:350 ||| FW
/  ||| S:350 E:352 ||| FW
chronic  ||| S:352 E:360 ||| FW
widespread  ||| S:360 E:371 ||| JJ
pain ||| S:371 E:375 ||| NN
;  ||| S:375 E:377 ||| :
( ||| S:377 E:378 ||| -LRB-
ii ||| S:378 E:380 ||| LS
)  ||| S:380 E:382 ||| -RRB-
headache  ||| S:382 E:391 ||| FW
/  ||| S:391 E:393 ||| FW
migraine ||| S:393 E:401 ||| FW
;  ||| S:401 E:403 ||| :
( ||| S:403 E:404 ||| -LRB-
iii ||| S:404 E:407 ||| LS
)  ||| S:407 E:409 ||| -RRB-
irritable  ||| S:409 E:419 ||| JJ
bowel  ||| S:419 E:425 ||| JJ
syndrome ||| S:425 E:433 ||| NN
;  ||| S:433 E:435 ||| :
( ||| S:435 E:436 ||| -LRB-
iv ||| S:436 E:438 ||| LS
)  ||| S:438 E:440 ||| -RRB-
temporomandibular  ||| S:440 E:458 ||| JJ
joint  ||| S:458 E:464 ||| JJ
disorder ||| S:464 E:472 ||| NN
;  ||| S:472 E:474 ||| :
( ||| S:474 E:475 ||| -LRB-
v ||| S:475 E:476 ||| LS
)  ||| S:476 E:478 ||| -RRB-
interstitial  ||| S:478 E:491 ||| JJ
cystitis ||| S:491 E:499 ||| NN
;  ||| S:499 E:501 ||| :
and  ||| S:501 E:505 ||| CC
( ||| S:505 E:506 ||| -LRB-
vi ||| S:506 E:508 ||| LS
)  ||| S:508 E:510 ||| -RRB-
endometriosis  ||| S:510 E:524 ||| FW
/  ||| S:524 E:526 ||| FW
vulvodynia  ||| S:526 E:537 ||| FW
/  ||| S:537 E:539 ||| FW
chronic  ||| S:539 E:547 ||| FW
pelvic  ||| S:547 E:554 ||| FW
pain ||| S:554 E:558 ||| FW
.  ||| S:558 E:560 ||| .
The  ||| S:560 E:564 ||| DT
occurrence  ||| S:564 E:575 ||| NN
of  ||| S:575 E:578 ||| IN
each  ||| S:578 E:583 ||| DT
of  ||| S:583 E:586 ||| IN
the  ||| S:586 E:590 ||| DT
above  ||| S:590 E:596 ||| JJ
syndromes  ||| S:596 E:606 ||| NNS
vary  ||| S:606 E:611 ||| VBP
between  ||| S:611 E:619 ||| IN
each  ||| S:619 E:624 ||| DT
other ||| S:624 E:629 ||| JJ
,  ||| S:629 E:631 ||| ,
and  ||| S:631 E:635 ||| CC
between  ||| S:635 E:643 ||| IN
studies ||| S:643 E:650 ||| NNS
.  ||| S:650 E:652 ||| .
Prevalence  ||| S:652 E:663 ||| JJ
ranges  ||| S:663 E:670 ||| NNS
from  ||| S:670 E:675 ||| IN
interstitial  ||| S:675 E:688 ||| JJ
cystitis ||| S:688 E:696 ||| NN
,  ||| S:696 E:698 ||| ,
with  ||| S:698 E:703 ||| IN
a  ||| S:703 E:705 ||| DT
prevalence  ||| S:705 E:716 ||| NN
of  ||| S:716 E:719 ||| IN
approximately  ||| S:719 E:733 ||| RB
14.5  ||| S:733 E:738 ||| CD
per  ||| S:738 E:742 ||| IN
100,000 ||| S:742 E:749 ||| CD
,  ||| S:749 E:751 ||| ,
to  ||| S:751 E:754 ||| TO
headache ||| S:754 E:762 ||| VB
,  ||| S:762 E:764 ||| ,
with  ||| S:764 E:769 ||| IN
some  ||| S:769 E:774 ||| DT
estimates  ||| S:774 E:784 ||| NNS
of  ||| S:784 E:787 ||| IN
lifetime  ||| S:787 E:796 ||| NN
prevalence  ||| S:796 E:807 ||| NN
to  ||| S:807 E:810 ||| TO
be  ||| S:810 E:813 ||| VB
around  ||| S:813 E:820 ||| IN
66 ||| S:820 E:822 ||| CD
% ||| S:822 E:823 ||| NN
.  ||| S:823 E:825 ||| .
Precise  ||| S:825 E:833 ||| JJ
risk  ||| S:833 E:838 ||| NN
estimates  ||| S:838 E:848 ||| NNS
vary  ||| S:848 E:853 ||| VBP
between  ||| S:853 E:861 ||| IN
studies ||| S:861 E:868 ||| NNS
,  ||| S:868 E:870 ||| ,
conditions ||| S:870 E:880 ||| NNS
,  ||| S:880 E:882 ||| ,
and  ||| S:882 E:886 ||| CC
exposures ||| S:886 E:895 ||| NNS
,  ||| S:895 E:897 ||| ,
although  ||| S:897 E:906 ||| IN
there  ||| S:906 E:912 ||| EX
is  ||| S:912 E:915 ||| VBZ
consistent  ||| S:915 E:926 ||| JJ
evidence  ||| S:926 E:935 ||| NN
to  ||| S:935 E:938 ||| TO
suggest  ||| S:938 E:946 ||| VB
an  ||| S:946 E:949 ||| DT
association  ||| S:949 E:961 ||| NN
between  ||| S:961 E:969 ||| IN
early  ||| S:969 E:975 ||| JJ
life  ||| S:975 E:980 ||| NN
adversity  ||| S:980 E:990 ||| NNS
and  ||| S:990 E:994 ||| CC
central  ||| S:994 E:1002 ||| JJ
sensitivity  ||| S:1002 E:1014 ||| NN
syndromes  ||| S:1014 E:1024 ||| NNS
( ||| S:1024 E:1025 ||| -LRB-
based  ||| S:1025 E:1031 ||| VBN
on  ||| S:1031 E:1034 ||| IN
the  ||| S:1034 E:1038 ||| DT
six  ||| S:1038 E:1042 ||| CD
syndromes  ||| S:1042 E:1052 ||| NN
under  ||| S:1052 E:1058 ||| IN
investigation ||| S:1058 E:1071 ||| NN
) ||| S:1071 E:1072 ||| -RRB-
.  ||| S:1072 E:1074 ||| .
In  ||| S:1074 E:1077 ||| IN
further  ||| S:1077 E:1085 ||| JJ
support  ||| S:1085 E:1093 ||| NN
of  ||| S:1093 E:1096 ||| IN
this ||| S:1096 E:1100 ||| DT
,  ||| S:1100 E:1102 ||| ,
a  ||| S:1102 E:1104 ||| DT
number  ||| S:1104 E:1111 ||| NN
of  ||| S:1111 E:1114 ||| IN
studies  ||| S:1114 E:1122 ||| NNS
have  ||| S:1122 E:1127 ||| VBP
also  ||| S:1127 E:1132 ||| RB
demonstrated  ||| S:1132 E:1145 ||| VBN
dose-risk  ||| S:1145 E:1155 ||| JJ
associations ||| S:1155 E:1167 ||| NNS
.  ||| S:1167 E:1169 ||| .
There  ||| S:1169 E:1175 ||| EX
is  ||| S:1175 E:1178 ||| VBZ
also  ||| S:1178 E:1183 ||| RB
considerable  ||| S:1183 E:1196 ||| JJ
consistency  ||| S:1196 E:1208 ||| NN
in  ||| S:1208 E:1211 ||| IN
the  ||| S:1211 E:1215 ||| DT
literature  ||| S:1215 E:1226 ||| NN
to  ||| S:1226 E:1229 ||| TO
suggest  ||| S:1229 E:1237 ||| VB
a  ||| S:1237 E:1239 ||| DT
strong  ||| S:1239 E:1246 ||| JJ
association  ||| S:1246 E:1258 ||| NN
between  ||| S:1258 E:1266 ||| IN
negative  ||| S:1266 E:1275 ||| JJ
psychological  ||| S:1275 E:1289 ||| JJ
and  ||| S:1289 E:1293 ||| CC
psychosocial  ||| S:1293 E:1306 ||| JJ
factors ||| S:1306 E:1313 ||| NNS
,  ||| S:1313 E:1315 ||| ,
and  ||| S:1315 E:1319 ||| CC
the  ||| S:1319 E:1323 ||| DT
occurrence  ||| S:1323 E:1334 ||| NN
of  ||| S:1334 E:1337 ||| IN
central  ||| S:1337 E:1345 ||| JJ
sensitivity  ||| S:1345 E:1357 ||| NN
syndromes  ||| S:1357 E:1367 ||| NNS
and ||| S:1367 E:1370 ||| CC
,  ||| S:1370 E:1372 ||| ,
again ||| S:1372 E:1377 ||| RB
,  ||| S:1377 E:1379 ||| ,
there  ||| S:1379 E:1385 ||| EX
is  ||| S:1385 E:1388 ||| VBZ
some  ||| S:1388 E:1393 ||| DT
evidence  ||| S:1393 E:1402 ||| NN
of  ||| S:1402 E:1405 ||| IN
a  ||| S:1405 E:1407 ||| DT
dose-risk  ||| S:1407 E:1417 ||| JJ
relationship ||| S:1417 E:1429 ||| NN
.  ||| S:1429 E:1431 ||| .
The  ||| S:1431 E:1435 ||| DT
majority  ||| S:1435 E:1444 ||| NN
of  ||| S:1444 E:1447 ||| IN
studies  ||| S:1447 E:1455 ||| NNS
in  ||| S:1455 E:1458 ||| IN
this  ||| S:1458 E:1463 ||| DT
field  ||| S:1463 E:1469 ||| NN
are  ||| S:1469 E:1473 ||| VBP
cross-sectional  ||| S:1473 E:1489 ||| JJ
or  ||| S:1489 E:1492 ||| CC
retrospective  ||| S:1492 E:1506 ||| NN
in  ||| S:1506 E:1509 ||| IN
design ||| S:1509 E:1515 ||| NN
,  ||| S:1515 E:1517 ||| ,
and  ||| S:1517 E:1521 ||| CC
caution  ||| S:1521 E:1529 ||| NN
is  ||| S:1529 E:1532 ||| VBZ
advised  ||| S:1532 E:1540 ||| VBN
when  ||| S:1540 E:1545 ||| WRB
interpreting  ||| S:1545 E:1558 ||| JJ
results ||| S:1558 E:1565 ||| NNS
.  ||| S:1565 E:1567 ||| .
It  ||| S:1567 E:1570 ||| PRP
is  ||| S:1570 E:1573 ||| VBZ
possible  ||| S:1573 E:1582 ||| JJ
-  ||| S:1582 E:1584 ||| :
indeed  ||| S:1584 E:1591 ||| RB
there  ||| S:1591 E:1597 ||| EX
is  ||| S:1597 E:1600 ||| VBZ
some  ||| S:1600 E:1605 ||| DT
evidence  ||| S:1605 E:1614 ||| NN
-  ||| S:1614 E:1616 ||| :
that  ||| S:1616 E:1621 ||| IN
some  ||| S:1621 E:1626 ||| DT
findings  ||| S:1626 E:1635 ||| NNS
may  ||| S:1635 E:1639 ||| MD
be  ||| S:1639 E:1642 ||| VB
subject  ||| S:1642 E:1650 ||| JJ
to  ||| S:1650 E:1653 ||| TO
recall  ||| S:1653 E:1660 ||| VB
bias ||| S:1660 E:1664 ||| NN
,  ||| S:1664 E:1666 ||| ,
and  ||| S:1666 E:1670 ||| CC
reverse  ||| S:1670 E:1678 ||| JJ
causation  ||| S:1678 E:1688 ||| NN
is  ||| S:1688 E:1691 ||| VBZ
also  ||| S:1691 E:1696 ||| RB
a  ||| S:1696 E:1698 ||| DT
potential  ||| S:1698 E:1708 ||| JJ
concern ||| S:1708 E:1715 ||| NN
.  ||| S:1715 E:1717 ||| .
However ||| S:1717 E:1724 ||| RB
,  ||| S:1724 E:1726 ||| ,
there  ||| S:1726 E:1732 ||| EX
are  ||| S:1732 E:1736 ||| VBP
also  ||| S:1736 E:1741 ||| RB
a  ||| S:1741 E:1743 ||| DT
number  ||| S:1743 E:1750 ||| NN
of  ||| S:1750 E:1753 ||| IN
prospective  ||| S:1753 E:1765 ||| JJ
studies  ||| S:1765 E:1773 ||| NNS
which  ||| S:1773 E:1779 ||| WDT
provide  ||| S:1779 E:1787 ||| VBP
more  ||| S:1787 E:1792 ||| RBR
robust  ||| S:1792 E:1799 ||| JJ
evidence ||| S:1799 E:1807 ||| NN
.  ||| S:1807 E:1809 ||| .
